Literature DB >> 4331739

Development of antibodies during long-term therapy with corticotrophin in rheumatoid arthritis. II. Zinc tetracosactrin (Depot Synacthen).

D Glass, G Nuki, J R Daly.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4331739      PMCID： PMC1005835          DOI： 10.1136/ard.30.6.593

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  9 in total

1.  THE PREPARATION OF I-131-LABELLED HUMAN GROWTH HORMONE OF HIGH SPECIFIC RADIOACTIVITY.

Authors:  F C GREENWOOD; W M HUNTER; J S GLOVER
Journal:  Biochem J       Date:  1963-10       Impact factor: 3.857

2.  Ten years of ACTH therapy.

Authors:  H F WEST
Journal:  Ann Rheum Dis       Date:  1962-09       Impact factor: 19.103

3.  Studies on ACTH-binding antibodies: characterization of immunological specificities.

Authors:  M L Aubert; J P Felber
Journal:  Acta Endocrinol (Copenh)       Date:  1969-11

4.  Antibodies to corticotrophin and their relation to adrenal function in children receiving corticotrophin therapy.

Authors:  J Landon; M Friedman; F C Greenwood
Journal:  Lancet       Date:  1967-03-25       Impact factor: 79.321

5.  Antibodies to synthetic corticotrophin.

Authors:  J P Felber; S H Ashcroft; A Villanueva; A Vannotti
Journal:  Nature       Date:  1966-08-06       Impact factor: 49.962

6.  Immunochemical study of beta-corticotropin-(1-24)-tetracosa-peptide.

Authors:  J Gelzer
Journal:  Immunochemistry       Date:  1968-01

7.  ACTH antibodies in patients receiving depot porcine ACTH to hasten recovery from pituitary-adrenal suppression.

Authors:  N Fleischer; K Abe; G W Liddle; D N Orth; W E Nicholson
Journal:  J Clin Invest       Date:  1967-02       Impact factor: 14.808

8.  Effect of corticotorphin on skeletal maturation and linear growth in six patients with severe asthma.

Authors:  A P Norman; S Sanders
Journal:  Lancet       Date:  1969-02-08       Impact factor: 79.321

9.  Immunologic studies of adrenocorticotropic hormone (ACTH): dissociation of biologic and immunologic activities.

Authors:  H Imura; L L Sparks; G M Grodsky; P H Forsham
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958
  9 in total
  3 in total

1.  Acquired Resistance to Corticotropin Therapy in Nephrotic Syndrome: Role of De Novo Neutralizing Antibody.

Authors:  Pei Wang; Yan Zhang; Yu Wang; Andrew S Brem; Zhangsuo Liu; Rujun Gong
Journal:  Pediatrics       Date:  2017-07       Impact factor: 7.124

2.  Relapse of Nephrotic Syndrome after Adrenocorticotropic Hormone-Induced Remission: Implications of Adrenocorticotropic Hormone Antibodies.

Authors:  Snehal Shrivastava; Bohan Chen; Lance D Dworkin; Deepak K Malhotra; Rujun Gong
Journal:  Am J Nephrol       Date:  2020-03-18       Impact factor: 3.754

3.  Spontaneous and tetracosactide-induced anti-ACTH antibodies in man.

Authors:  Earn H Gan; Katie MacArthur; Anna L Mitchell; Abhijit Joshi; Patricia Crock; Simon H S Pearce
Journal:  Clin Endocrinol (Oxf)       Date:  2015-06-25       Impact factor: 3.478
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.